Phase 4 N=70 Ondansetron for Bipolar Disorder and Alcohol Use Disorders
Bipolar Disorder · Alcohol Use Disorder · Dual Diagnosis
Primary: Hamilton Rating Scale for Depression (HAMD) — 13.77; 14.23; 8.52; 8.86 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=13 Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada
Multiple Sclerosis
Primary: Number of Participants Who Provided Whole Blood Samples for DNA Extraction and Analysis — 12; 12; 12; 12 Participants
Phase 4 N=141 Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting
Post-operative Nausea and Vomiting
Primary: Nausea Scale — 3.5; 4.0; 4.0; 2.0 score on a scale
Phase 4 N=220 The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity
Rotavirus Infection · Vaccine Response Impaired · Vaccine Virus Shedding
Primary: Number (or Percentage) of Infants in Each Study Arm Who Test Positive for Fecal Rotavirus Vaccine-strain Virus Shedding Post-vaccination — 63; 55 Participants
Phase 4 N=44 A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Schizophrenia · Schizoaffective Disorder · First Episode Psychosis
Primary: Percentage Of Days With Good Patch Coverage — 64.34; 62.99; 62.51; 63.37 percentage of days
Phase 4 N=17 Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children
Traumatic Brain Injury · Attention Deficit Disorder
Primary: Assessing Severity of Symptoms Associated With Attention-deficit/Hyperactivity Disorder (ADHD) in Children When Using Vyvanse Versus Placebo by Administering the…
Phase 4 N=121 Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Alzheimer Disease · Mild Cognitive Impairment · Delirium, Dementia, Amnestic, Cognitive Disorders
Primary: Change Over Time in Selective Reminding Test (SRT) Scores — 36.14; 21.19; 39.99; 24.10 Words
Phase 4 N=714 Colchicine in Percutaneous Coronary Intervention
Coronary Artery Disease · Acute Coronary Syndrome
Primary: Number of Participants With Peri-procedural Myocardial Necrosis — 118; 122 Participants — p=<0.05
Phase 4 N=89 the Analgesic Duration of Dexmedetomidine Compared to Dexamethasone as Adjuncts to Single Shot Interscalene Block
Opioid Use, Unspecified
Primary: Opioid Requirements (Morphine Equivalents) — 15; 15; 22.5 morphine milligram equivalent
Phase 4 N=162 Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO
Central Retinal Vein Occlusion
Primary: The Proportion of Participants Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to…
Phase 4 N=11 Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients
Gastrointestinal Symptoms · Heart Transplantation
Primary: GI Tolerability as Measured by GSRS — 55.67; 34.17 score on a scale
Phase 4 N=44 Renoprotective Effects of Dapagliflozin in Type 2 Diabetes
Diabetes Mellitus, Type 2 · Diabetic Nephropathies
Primary: Glomerular Filtration Rate (GFR) in ml/Min — 104; 109 ml/min
Phase 4 N=9 Cognitive Decline in Non-demented PD
Parkinson's Disease
Primary: Attention Network Effects
Phase 4 N=40 RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF
Breast Cancer · Infertility
Primary: Mature Oocyte Yield — 5.1; 7.9 oocytes — p=0.31
Phase 4 N=109 Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users
Bleeding · Implants · Breakthrough Bleeding
Primary: Total Number of Consecutive Bleeding-free Days in First 30 Days From Day 1 of First Treatment (TX1) — 18.5; 8.7 days